Zoetis Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zoetis Inc. (NYSE: ZTS) resulting from allegations that Zoetis may have issued materially misleading business information to the investing public.

If you purchased Zoetis securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Zoetis securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On April 12, 2024, before the market opened, The Wall Street Journal released an article entitled “What Killed Their Pets? Owners Blame Meds, but Vets Aren’t Sure.” This article discussed possible side effects caused by Librela and Solensia, two drugs which are produced by Zoetis, and are respectively used to treat arthritis in dogs and cats. The article also stated “[h]ealth regulators in the U.S. and Europe—which have received thousands of reports of side effects—are conducting reviews” and that “[t]he FDA received more than 3,800 reports of side effects concerning the drugs through the end of last year.”

On this news, Zoetis’ stock price fell $12.75 per share, or 7.8%, to close at $149.98 per share on April 12, 2024.

Follow us on:
Company Name: Zoetis Inc.
Stock Symbol: ZTS
Class Period: N/A
Court: N/A

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top